Equities analysts expect that Forty Seven Inc (NASDAQ:FTSV) will post earnings of ($0.66) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Forty Seven’s earnings, with estimates ranging from ($0.71) to ($0.60). The firm is expected to announce its next earnings report on Tuesday, February 12th.
According to Zacks, analysts expect that Forty Seven will report full year earnings of ($3.42) per share for the current fiscal year, with EPS estimates ranging from ($4.03) to ($2.38). For the next fiscal year, analysts forecast that the firm will post earnings of ($2.74) per share, with EPS estimates ranging from ($2.93) to ($2.37). Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Forty Seven.
Forty Seven (NASDAQ:FTSV) last issued its earnings results on Tuesday, November 13th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.17).
A number of equities analysts have recently issued reports on the company. Zacks Investment Research raised Forty Seven from a “sell” rating to a “hold” rating in a research note on Friday, November 9th. HC Wainwright assumed coverage on Forty Seven in a research note on Friday, November 30th. They set a “buy” rating and a $21.00 target price for the company. ValuEngine raised Forty Seven from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Finally, Morgan Stanley increased their target price on Forty Seven from $25.00 to $26.00 and gave the stock an “overweight” rating in a research note on Thursday, October 11th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $25.60.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC purchased a new position in Forty Seven in the 2nd quarter valued at approximately $3,751,000. Laurion Capital Management LP purchased a new position in Forty Seven in the 2nd quarter valued at approximately $2,000,000. Millennium Management LLC purchased a new position in Forty Seven in the 2nd quarter valued at approximately $1,940,000. BlackRock Inc. purchased a new position in Forty Seven in the 2nd quarter valued at approximately $548,000. Finally, Acuta Capital Partners LLC purchased a new position in Forty Seven in the 2nd quarter valued at approximately $1,168,000. 41.44% of the stock is owned by hedge funds and other institutional investors.
Shares of FTSV stock remained flat at $$18.41 during trading hours on Monday. The stock had a trading volume of 97,379 shares, compared to its average volume of 90,909. Forty Seven has a fifty-two week low of $12.02 and a fifty-two week high of $19.82.
About Forty Seven
Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; and FSI-189, an antibody that binds to SIRPa for the treatment of solid tumors.
Recommended Story: How to Calculate Compound Annual Growth Rate (CAGR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Forty Seven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forty Seven and related companies with MarketBeat.com's FREE daily email newsletter.